These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8864318)

  • 21. [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)].
    Scheen AJ
    Rev Med Liege; 1998 Jan; 53(1):41-4. PubMed ID: 9555183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.
    Yin OQ; Tomlinson B; Chow AH; Chow MS
    Clin Pharmacokinet; 2003; 42(2):179-92. PubMed ID: 12537516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of the H2- receptor antagonist ranitidine in man.
    McNeil JJ; Mihaly GW; Anderson A; Marshall AW; Smallwood RA; Louis WJ
    Br J Clin Pharmacol; 1981 Sep; 12(3):411-5. PubMed ID: 6117305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levofloxacin- vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.
    Gisbert JP; Gisbert JL; Marcos S; Moreno-Otero R; Pajares JM
    Helicobacter; 2007 Feb; 12(1):68-73. PubMed ID: 17241304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study.
    Tam YH; Yeung CK; Lee KH
    Aliment Pharmacol Ther; 2006 Jul; 24(1):81-6. PubMed ID: 16803605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
    Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
    Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
    Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine.
    Koch KM; O'Connor-Semmes RL; Davis IM; Yin Y
    J Pharm Sci; 1998 Sep; 87(9):1097-100. PubMed ID: 9724561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds.
    Nwokolo CU; Prewett EJ; Sawyerr AM; Hudson M; Pounder RE
    Gastroenterology; 1991 Oct; 101(4):889-94. PubMed ID: 1889712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and bioequivalence study of ranitidine film tablets in healthy male subjects.
    Gschwend MH; Guserle R; Erenmemişoglu A; Martin W; Tamur U; Kanzik I; Hincal AA
    Arzneimittelforschung; 2007; 57(6):315-9. PubMed ID: 17688076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of age on the pharmacokinetics of ranitidine in healthy Mexican volunteers.
    Pérez-Guillé G; Guillé-Pérez A; Toledo-López A; Juárez-Olguín H; Flores Pérez C; Flores-Pŕez J; Carrasco-Portugal M; Lares-Asseff I; Camacho-Vieyra A
    Proc West Pharmacol Soc; 2005; 48():84-8. PubMed ID: 16416668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.
    Akyildiz M; Akay S; Musoglu A; Tuncyurek M; Aydin A
    Eur J Intern Med; 2009 Jan; 20(1):53-7. PubMed ID: 19237093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
    Gisbert JP; Fuentes J; Carpio D; Tito L; Guardiola J; Tomas A; Olivares D; Calvet X
    Aliment Pharmacol Ther; 2005 May; 21(10):1249-53. PubMed ID: 15882246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of GR122311X, a bismuth compound with H2-antagonist activity, on 24-hour intragastric acidity.
    Prewett EJ; Nwokolo CU; Hudson M; Sawyerr AM; Fraser A; Pounder RE
    Aliment Pharmacol Ther; 1991 Oct; 5(5):481-90. PubMed ID: 1686562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
    Stass H; Böttcher MF; Ochmann K
    Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No effect of short term ranitidine intake on diclofenac pharmacokinetics.
    Leucuţa A; Vlase L; Farcau D; Nanulescu M
    Rom J Gastroenterol; 2004 Dec; 13(4):306-8. PubMed ID: 15624028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens.
    Fraser AG; Lam WM; Luk YW; Sercombe J; Sawyerr AM; Hudson M; Samloff IM; Pounder RE
    Gut; 1993 Mar; 34(3):338-42. PubMed ID: 8472980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
    James LP; Stowe CD; Farrar HC; Menendez AA; Argao EA
    J Clin Pharmacol; 1999 Dec; 39(12):1242-7. PubMed ID: 10586389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranitidine bismuth citrate therapy.
    Harris A; Misiewicz JJ
    Aliment Pharmacol Ther; 1996 Dec; 10(6):1035. PubMed ID: 8971307
    [No Abstract]   [Full Text] [Related]  

  • 40. A lack of pharmacokinetic interaction between ranitidine and piroxicam.
    Dixon JS; Lacey LF; Pickup ME; Langley SJ; Page MC
    Eur J Clin Pharmacol; 1990; 39(6):583-6. PubMed ID: 1982764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.